Compare Freshworks Inc (FRSH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Freshworks Inc trades at $10.61 (market cap $2.93B), while Regeneron Pharmaceuticals Inc trades at $678.9 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 23.8× Freshworks Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| FRSH | REGN | |
|---|---|---|
Market Cap | $2.93B | $69.66B |
Sector | Technology | Health |
52-Week High | $14.77 | $812.27 |
52-Week Low | $6.88 | $542.52 |
Enterprise Value | $2.19B | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.88, up 3.92% with a bullish technical signal and strong revenue growth from $720M in 2024 to $839M in 2025. The company achieved profitability in 2025 with net income of $184M, reversing prior losses. Recent news highlights AI product launches and a key partnership with Vanquis, while analyst consensus is split evenly between Buy and Hold ratings.
The outlook is positive with accelerating revenue and a path to sustained profitability, though high EV/EBITDA of 51.08 suggests premium valuation. Risks include execution on AI initiatives and competitive pressure in SaaS. Wall Street sees 26-38% upside potential based on price targets, making FRSH an attractive growth story if margins expand as projected.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
